Skip to content

Clinical Trials

Clinical Trials

RESIN



Patients enrolled

Real-world data from RESiN support evidence on the efficacy and safety of SIRT with
SIR-Spheres® Y-90 resin microspheres2-4

Results from the mCRC cohort3,4



Patients enrolled



Results from the HCC cohort2,3



HCC Patients enrolled


Register

Abbreviations:
HCC: Hepatocellular carcinoma ; mCRC: metastatic colorectal cancer ; ECOG PS: Eastern Cooperative Oncology Group - Performance Status ; SBRT: Stereotactic Body Radiation Therapy ; PVE: Portal vein embolization ; BSA : Body surface area ; OS: Overall survival ; PFS: Progression-free survival ; BCLC: Barcelona clinic liver cancer ;

References:

  1. Sirtex Press Release Aug 2020. https://appliedradiationoncology.com/articles/sirtex-completes-u-s-resin-registry-enrollment. Last access: Aug 12th 2021. 2. Frantz S et al. J Vasc Interv Radiol 2021; 32: 845–852. 3. Brown D et al. J Gastrointest Oncol 2021; 12(2):639-657. 4. Emmons et al. Radiol 2022; doi: 10.1148/radiol.220387.

SIR-Spheres® Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) or unresectable metastatic liver tumors from primary colorectal cancer (mCRC) in patients refractory to or intolerant of chemotherapy.

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.